VACCINATION & PREVENTION
COVID-19 and influenza vaccines at the same visit
We recommend receiving influenza and COVID-19 vaccines at the same visit for adults aged 65 or older and other patients at higher risk of severe illness.
The main aim is to reduce severe illness and burdens such as hospitalization. We discuss vaccination in light of your health, vaccination history, previous reactions and preferences.
Medically reviewed by Koshiro Nishimoto, MD, PhD (Director)
Updated October 9, 2026
Who may benefit most
Vaccination is particularly relevant for people at higher risk of severe COVID-19, including:
- Adults aged 65 or older
- People with chronic heart disease, such as heart failure or coronary artery disease
- People with chronic lung disease, such as COPD or interstitial lung disease
- People with chronic kidney disease, including people receiving dialysis
- People with diabetes
- People whose immune function is reduced by illness or treatment, such as during cancer treatment, after an organ transplant or while taking immunosuppressive medicines
COVID-19 vaccination is also recommended for people younger than 65 with these risk factors. Please ask us whether vaccination is appropriate and when it should be scheduled during treatment.
A joint statement published on September 1, 2026 by the Japanese associations for infectious diseases, respiratory medicine and vaccinology strongly recommends COVID-19 vaccination for eligible routine-program recipients, including older adults.
Joint statement on routine COVID-19 vaccination for fiscal year 2026 (Japanese)
Vaccination for people younger than 65
According to the Japanese Association for Infectious Diseases recommendations of September 30, 2026, COVID-19 deaths among people aged 40–64 in Japan in 2025 exceeded influenza deaths in the same age group. Preventing severe COVID-19 is also relevant for this age group.
People outside the routine program can receive vaccination privately. For people without underlying conditions, the decision considers exposure, living and working circumstances, vaccination benefits and possible adverse reactions, and personal preferences.
The association particularly recommends an updated COVID-19 vaccine for health-care workers and staff at social welfare facilities. We can discuss vaccination in light of your individual circumstances.
Japanese Association for Infectious Diseases recommendations, September 2026 (Japanese)
A US study of nearly 300,000 people
A study published in The New England Journal of Medicine (NEJM) in 2025 used US Veterans Affairs health records to examine the association between 2024–2025 COVID-19 vaccination and subsequent COVID-19-associated emergency visits, hospitalizations and deaths.
People included in the comparison295,971 people
Influenza + COVID-19
Both vaccines on the same day164,132 people
Influenza only
No COVID-19 vaccine on that day131,839 people
Follow-up lasted up to 180 days from vaccination. Using an influenza-vaccinated comparison group helps reduce differences related to vaccination habits and use of health care.
All participants had received at least one 2023–2024 COVID-19 vaccine dose. The study therefore assessed the additional benefit of the updated seasonal dose, rather than comparing vaccination with never having been vaccinated.
How did the estimated risks differ?
After statistical adjustment for differences such as age and medical conditions, the group receiving both vaccines had lower estimated risks of COVID-19-associated emergency visits, hospitalizations and deaths.
All bars use the same scale, from 0 to 0.8%.
Emergency or urgent care visit
Relative reduction: 29.3%Hospitalization
Relative reduction: 39.2%Death within 30 days of a positive test*
Relative reduction: 64.0%Any of the three outcomes
Relative reduction: 28.3%Clinic-created chart using the adjusted 180-day estimates in NEJM Table 2. Both vaccines means influenza and COVID-19 vaccines on the same day.
*Death was defined as death within 30 days after a positive SARS-CoV-2 test, without restriction by cause. Other causes may be included if that condition is met; deaths without a qualifying positive test are not counted in this endpoint. The study did not evaluate adverse events or vaccine-attributable deaths and cannot determine safety or the overall effect on all-cause mortality.
Safety of same-day vaccination
Influenza and COVID-19 vaccines may be given at the same visit when the doctor considers it medically appropriate. This can reduce the number of visits needed for vaccination.
Reactions may include pain at the injection site, fatigue, headache or fever. Some studies report more temporary reactions with coadministration, so we review your health and previous reactions before vaccination.
Rare serious allergic reactions (anaphylaxis) and myocarditis or pericarditis have also been reported. The following US mRNA COVID-19 vaccine data provide reference estimates of frequency.
| Adverse event | Estimated percentage | Population and observation period |
|---|---|---|
| Anaphylaxis | About 0.0005% | mRNA vaccines. Estimate in current CDC guidance, based on the original-formula primary series in people aged 12 or older, on vaccination day and the following day. |
| Myocarditis or pericarditis | About 0.0008% | 2023–2024 mRNA formulation, ages 6 months through 64 years; 1–7 days after vaccination. |
| Myocarditis or pericarditis (young males) | About 0.0027% | The same 2023–2024 data, males aged 12–24; 1–7 days after vaccination. |
CDC: anaphylaxis frequency / FDA: myocarditis/pericarditis frequency, June 2025
Seek prompt medical attention for chest pain, difficulty breathing or palpitations after vaccination.
Japan Ministry of Health: coadministration and adverse reactions (Japanese) / Japanese Association for Infectious Diseases recommendations (Japanese)
Fees, questions and appointments
All listed amounts include tax.
For eligible routine-program recipients aged 65 or older who are registered residents of Miyazaki City, patient contributions for fiscal year 2026 are:
- Influenza vaccine
- ¥1,500
- COVID-19 vaccine
- ¥4,500
- Both vaccines at the same visit
- Total ¥6,000
The routine COVID-19 vaccination period is October 1, 2026 through March 31, 2027. Recipients of public assistance are exempt from both contributions on presentation of their certificate.
The routine program also includes residents aged 60–64 with specified severe heart, kidney or respiratory impairment that profoundly limits daily activities, or HIV-related immune impairment that makes daily life almost impossible. A medical recommendation does not by itself establish eligibility for the public program.
For other patients, we explain eligibility and costs individually. If your registered residence is outside Miyazaki City, check your municipality’s current program.
Miyazaki City fiscal year 2026 vaccination program (Japanese) / Clinic fees
Tell reception or your doctor that you would like influenza and COVID-19 vaccines at the same visit. We review your medical conditions, treatment, vaccination history and previous reactions, then explain scheduling and appointment arrangements.
Please also tell us if you recently had COVID-19 and when it occurred. We discuss whether and when to vaccinate in light of your health and treatment.
This page provides general patient information. Individual suitability for vaccination is assessed during consultation.
- Cai M, Xie Y, Al-Aly Z. NEJM 2025;393:1612–1623. DOI: 10.1056/NEJMoa2510226
- Joint statement on routine COVID-19 vaccination, September 1, 2026 (Japanese)
- Japanese Association for Infectious Diseases, COVID-19 vaccine recommendations, version 12 (Japanese)
- Japan Ministry of Health, COVID-19 vaccine Q&A (Japanese)
- Miyazaki City fiscal year 2026 vaccination information (Japanese)
- CDC, Contraindications and Precautions, updated September 2026
- FDA, updated myocarditis/pericarditis warning for mRNA vaccines, June 2025